MedTrace Logo

Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects

NCT00954252 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2015-02-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of single oral doses of CHF 5074 in young healthy male volunteers.

Conditions

Interventions

DRUG

CHF 5074

1x, oral capsule, single dose

DRUG

placebo

placebo, oral capsule, single dose

DRUG

CHF 5074

2x, oral capsule, single dose

DRUG

CHF 5074

4x, oral capsule, single dose

DRUG

CHF 5074

8x, oral capsule, single dose

DRUG

CHF 5074

16x, oral capsule, single dose

DRUG

CHF 5074

24x, oral capsule, single dose

Sponsors & Collaborators

  • CERESPIR

    lead INDUSTRY

Principal Investigators

  • Joel S Ross, MD, FACP · Iberica Clinical Research Center

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00954252 on ClinicalTrials.gov